<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846144</url>
  </required_header>
  <id_info>
    <org_study_id>0136-08-HMO</org_study_id>
    <secondary_id>not available</secondary_id>
    <nct_id>NCT00846144</nct_id>
  </id_info>
  <brief_title>The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients</brief_title>
  <official_title>This Study is a Small Preliminary Study to Evaluate the Possibility of Performing a Phase 1 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the CDs rat model, beta-cell dysfunction and pancreatic exocrine damage are triggered and
      prevented by altering dietary Cu content suggesting a chronic and acute role for Cu. These
      abnormalities become apparent when the CDs rats are exposed to high sucrose low copper diet,
      triggering a vicious sequence of events: exocrine damage, recruitment of macrophages
      expressing IL-1beta leading to oxidative stress and even more reduction in the activity of
      Cu-dependent enzymes (chronic effect). When Cu levels are re-established (acute effect) they
      may prevent the inhibitory effect of IL-1beta on insulin release and may restore the activity
      of enzymes inhibited by IL-1beta. In this study we will identify humans with marginal Cu
      status that may benefit from copper supplementation to normalize their GSIS. These patients
      will be given a daily Cu supplement (3mg/d), or placebo for a period of 6 months. GSIS,
      pancreatic dysfunction and biomarkers of marginal Cu status will be measured in different
      blood components before and every 4 weeks during treatments or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify humans with marginal Cu status that may benefit from copper supplementation and normalize their GSIS.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>copper sulfate</intervention_name>
    <description>copper sulfate 3mg/d for a period of 6 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetic subjects with BMI &lt; 33

          -  HbA1C &lt; 8

          -  plasma copper levels of &lt; 90 ul/dl

        Exclusion Criteria:

          -  patients with bad physical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Itamar Raz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Itamar Raz, Prof</last_name>
    <phone>972-2-6778021</phone>
    <email>ntv502@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Unit, Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Weksler-Zangen S, Raz I, Lenzen S, JÃ¶rns A, Ehrenfeld S, Amir G, Oprescu A, Yagil Y, Yagil C, Zangen DH, Kaiser N. Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes. 2008 Feb;57(2):279-87. Epub 2007 Oct 31.</citation>
    <PMID>17977959</PMID>
  </reference>
  <reference>
    <citation>Weksler-Zangen S, Yagil C, Zangen DH, Ornoy A, Jacob HJ, Yagil Y. The newly inbred cohen diabetic rat: a nonobese normolipidemic genetic model of diet-induced type 2 diabetes expressing sex differences. Diabetes. 2001 Nov;50(11):2521-9.</citation>
    <PMID>11679430</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Itamar Raz</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Glucose stimulated insulin secretion</keyword>
  <keyword>copper</keyword>
  <keyword>cytokines</keyword>
  <keyword>diabetes</keyword>
  <keyword>Reduction in insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Copper</mesh_term>
    <mesh_term>Copper Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

